Neuraxis, Inc. (NRXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuraxis, Inc. (NRXS) has a cash flow conversion efficiency ratio of -0.214x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.23 Million) by net assets ($5.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neuraxis, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Neuraxis, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Neuraxis, Inc. total liabilities for a breakdown of total debt and financial obligations.
Neuraxis, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuraxis, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acset Indonusa Tbk
JK:ACST
|
-0.226x |
|
Gambling.com Group Ltd
NASDAQ:GAMB
|
-0.114x |
|
Bigbloc Construction Limited
NSE:BIGBLOC
|
0.063x |
|
Alithya Group Inc
NASDAQ:ALYAF
|
0.152x |
|
Graha Layar Prima Tbk
JK:BLTZ
|
0.257x |
|
Hun Yenilenebilir Enerji Uretim AS
IS:HUNER
|
0.014x |
|
DT Cloud Star Acquisition Corporation Units
NASDAQ:DTSQU
|
-0.001x |
|
TIAN GE INT.HLDGS DL-0001
F:04T
|
N/A |
Annual Cash Flow Conversion Efficiency for Neuraxis, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Neuraxis, Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Neuraxis, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.40 Million | $-6.43 Million | -1.892x | +35.84% |
| 2024-12-31 | $2.07 Million | $-6.10 Million | -2.949x | -161.82% |
| 2023-12-31 | $-1.40 Million | $-6.69 Million | 4.770x | +1057.01% |
| 2022-12-31 | $-5.57 Million | $-2.30 Million | 0.412x | -84.76% |
| 2021-12-31 | $-825.66K | $-2.23 Million | 2.706x | +207.46% |
| 2020-12-31 | $1.64 Million | $-4.14 Million | -2.518x | -- |
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional … Read more